ShiSiYao Group (02005) announces latest progress in the development of multiple innovative drugs.

The Zhixin Finance app reported that S4 Pharma Group (02005) announced that the clinical trials of single-dose administration of SYN045 tablets 50mg and 100mg, as well as multiple-dose administration of 25mg, have been completed recently. The study results show that the pharmacokinetic characteristics in the human body are good, and the safety and tolerability have been significantly improved compared to similar drugs targeting the same receptors, which is conducive to achieving long-term oral administration. As of now, the SYN045 project has submitted a total of 18 invention patents, including 5 international invention patents (with international PCT applications submitted); and 13 domestic invention patents (including 5 invention patents related to compounds, crystal forms, formulations, etc. have been granted).